Table 3.
Competing risk analysis: genotype distribution of single-nucleotide polymorphism rs3814113 by affection status and associations with ovarian and breast cancer risk*
| Gene | rs3814113 genotype | Unaffected subjects, No. (%) | Ovarian cancer patients, No. (%) | Ovarian cancer |
Breast cancer patients, No. (%) | Breast cancer |
||
| HR (95% CI) | P† | HR (95% CI) | P† | |||||
| BRCA1 | TT | 1569 (44.4) | 699 (51.3) | 1 (ref) | 2208 (43.0) | 1 (ref) | ||
| CT | 1562 (44.2) | 555 (40.7) | 0.82 (0.71 to 0.94) | 2329 (45.4) | 1.07 (0.98 to 1.15) | |||
| CC | 403 (11.4) | 109 (8.0) | 0.60 (0.47 to 0.76) | 595 (11.6) | 1.04 (0.91 to 1.18) | |||
| 2 df test | 2.8 × 10−5 | .28 | ||||||
| Per-allele analysis | 0.79 (0.71 to 0.87) | 4.4 × 10−6 | 1.03 (0.98 to 1.10) | .24 | ||||
| BRCA2 | TT | 1012 (45.4) | 191 (50.4) | 1 (ref) | 1502 (46.5) | 1 (ref) | ||
| CT | 969 (43.5) | 159 (42.0) | 0.82 (0.65 to 1.04) | 1376 (42.6) | 0.95 (0.85 to 1.06) | |||
| CC | 247 (11.1) | 29 (7.6) | 0.61 (0.40 to 0.93) | 352 (10.9) | 0.96 (0.81 to 1.15) | |||
| 2 df test | .042 | .63 | ||||||
| Per-allele analysis | 0.80 (0.67 to 0.95) | .012 | 0.97 (0.90 to 1.05) | .45 | ||||
| BRCA1/2 combined | TT | 2581 (44.8) | 890 (51.1) | 1 (ref) | 3710 (44.4) | 1 (ref) | ||
| CT | 2531 (43.9) | 714 (41.0) | 0.82 (0.73 to 0.92) | 3705 (44.3) | 1.02 (0.95 to 1.08) | |||
| CC | 650 (11.3) | 138 (7.9) | 0.60 (0.49 to 0.74) | 947 (11.3) | 1.01 (0.91 to 1.12) | |||
| 2 df test | 1.1 × 10−6 | .89 | ||||||
| Per-allele analysis | 0.79 (0.73 to 0.86) | 1.6 × 10−7 | 1.01 (0.96 to 1.06) | .73 | ||||
*
CI = confidence interval; HR = hazard ratio; ref = referent.
†
A robust Wald test statistic was used. All statistical tests were two-sided.